Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

26 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Effects of the single and combined treatment with dopamine agonist, somatostatin analog and mTOR inhibitors in a human lung carcinoid cell line: an in vitro study.
Pivonello C, Rousaki P, Negri M, Sarnataro M, Napolitano M, Marino FZ, Patalano R, De Martino MC, Sciammarella C, Faggiano A, Rocco G, Franco R, Kaltsas GA, Colao A, Pivonello R. Pivonello C, et al. Among authors: patalano r. Endocrine. 2017 Jun;56(3):603-620. doi: 10.1007/s12020-016-1079-2. Epub 2016 Sep 29. Endocrine. 2017. PMID: 27688013
Effect of combined treatment with a pan-PI3K inhibitor or an isoform-specific PI3K inhibitor and everolimus on cell proliferation in GH-secreting pituitary tumour in an experimental setting.
Pivonello C, Patalano R, Solari D, Auriemma RS, Frio F, Vitulli F, Grasso LFS, Di Cera M, De Martino MC, Cavallo LM, Cappabianca P, Colao A, Pivonello R. Pivonello C, et al. Among authors: patalano r. Endocrine. 2018 Dec;62(3):663-680. doi: 10.1007/s12020-018-1677-2. Epub 2018 Jul 31. Endocrine. 2018. PMID: 30066286
The treatment with pasireotide in Cushing's disease: effect of long-term treatment on clinical picture and metabolic profile and management of adverse events in the experience of a single center.
Simeoli C, Ferrigno R, De Martino MC, Iacuaniello D, Papa F, Angellotti D, Pivonello C, Patalano R, Negri M, Colao A, Pivonello R. Simeoli C, et al. Among authors: patalano r. J Endocrinol Invest. 2020 Jan;43(1):57-73. doi: 10.1007/s40618-019-01077-8. Epub 2019 Jul 16. J Endocrinol Invest. 2020. PMID: 31313243 Free PMC article. Clinical Trial.
Vitamin D reverts resistance to the mTOR inhibitor everolimus in hepatocellular carcinoma through the activation of a miR-375/oncogenes circuit.
Provvisiero DP, Negri M, de Angelis C, Di Gennaro G, Patalano R, Simeoli C, Papa F, Ferrigno R, Auriemma RS, De Martino MC, Colao A, Pivonello R, Pivonello C. Provvisiero DP, et al. Among authors: patalano r. Sci Rep. 2019 Aug 12;9(1):11695. doi: 10.1038/s41598-019-48081-9. Sci Rep. 2019. PMID: 31406139 Free PMC article.
Resistance to Dopamine Agonists in Pituitary Tumors: Molecular Mechanisms.
Pivonello C, Patalano R, Negri M, Pirchio R, Colao A, Pivonello R, Auriemma RS. Pivonello C, et al. Among authors: patalano r. Front Endocrinol (Lausanne). 2022 Jan 12;12:791633. doi: 10.3389/fendo.2021.791633. eCollection 2021. Front Endocrinol (Lausanne). 2022. PMID: 35095761 Free PMC article. Review.
26 results